Abstract
The aim of this paper is to determine whether the incidence of estrogen-, progesterone-, CEA-, and ferritin-positive staining of primary tumors, by using the PAP method, is related to the prognosis of breast cancer status. A significantly higher incidence (71 per cent) of CEA-positive tumors was observed in patients who had a recurrence of breast cancer within 2 years after radical operation. Patients, whose tumors were positive in estrogen or negative in CEA, showed a relatively good prognosis, even after a recurrence of the disease. Distant metastases were seen in most of the patients positive in CEA (78 per cent). Before the recurrence of breast cancer, those patients positive in progesterone had a good prognosis. After the recurrence, however, there was no relationship between the prognosis of recurrent disease and the progesterone-staining of primary tumors. Our data suggest that the immunohistological staining of estrogen, progesterone and CEA might offer the effective prognostic indices in breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pertschuk LP, Tobin EH, Gaetjens F, Carter AC, Degenshein GA, Bloom ND, Brigati DJ. Histochemical assay of estrogen and progesterone receptor in breast cancer. Cancer 1980; 46: 2896–2901.
Shimizu M, Wajima O, Miura M, Katayama I. PAP immunoperoxidase method demonstrating endogenous estrogen in breast carcinoma. Cancer 1983; 52: 486–492.
Shimizu M, Wajima O, Miura M, Kobayashi M, Maruyama M, Iino Y, Izuo M, Katayama I. Demonstration of estrogen and progesterone receptor in breast carcinomas by immunoperoxidase method; its clinical significance. J Saitama Med School 1981; 8: 193–197.
Kojima O, Tanioku T, Kitagawa N, Uehara Y, Majima T, Ikeda E, Iwai N, Fujita Y, Majima S. Comparative study of CEA staining in gastric and colorectal cancer tissues. Gastroenterologia Japonica 1984; 19: 18–23.
Mayanard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 1978; 38: 4292–4295.
Horwitz KB, McGire WL. Specific progesterone receptors in human breast cancer. Steroid 1975; 25: 497–502.
Shousha S, Lyssiotis T. Correlation of carcinoem-bryonic antigen in tissue sections with spread of mammary carcinoma. Histopathology 1978; 2: 433–447.
Smith SR, Howell A, Morrison JM. The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. Br J Cancer 1982; 46: 757–764.
Tormey DC, Waalkes TP. Clinical correlation between CEA and breast cancer. Cancer 1978; 42: 1507–1511.
Kojima O, Ikeda E, Uehara Y, Majima T, Fujita Y, Majima S. Correlation between carcinoembryonic antigen in gastric cancer tissue and survival of patients with gastric cancer. Gann 1984; 75: 230–236.
Marcus DM, Zinberg N. Measurement of serum ferritin by radioimmunoassay: Results in normal individuals and patients with breast cancer. J Nat Cancer Inst 1975; 55: 791–795.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Majima, T., Kojima, O., Uehara, Y. et al. Immunohistochemical demonstration of estrogen, progesterone, CEA and ferritin in breast cancer and their clinical value for the prediction of early postoperative recurrence. The Japanese Journal of Surgery 17, 243–247 (1987). https://doi.org/10.1007/BF02470695
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02470695